Notably, we confirmed mutations in known cancer genes such as BRCA2 and TP53, and also identified potentially novel, canine-specific drivers—HECTD4 in malignant tumors and NIPBL in epithelial subtypes—suggesting their role in tumor development and progression. The gene discussed is BRCA2; the disease is neoplasm.